Akouos to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Akouos (NASDAQ: AKUS) is a precision genetic medicine company focused on developing gene therapies for individuals with disabling hearing loss. On November 23, 2020, CEO Manny Simons participated in a pre-recorded fireside chat for the Piper Sandler 32nd Annual Virtual Healthcare Conference scheduled for December 1-3, 2020. The chat will be available for on-demand viewing on Akouos's website starting today and for 14 days following the conference.

Founded in 2016 and headquartered in Boston, Akouos aims to restore high-acuity hearing using its proprietary gene therapy platform.

BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, participated in a pre-recorded fireside chat that will be published today as part of the Piper Sandler 32^nd Annual Virtual Healthcare Conference taking place December 1 to 3, 2020.

The fireside chat will be available for on-demand viewing through the investor relations section of Akouos’s website at www.akouos.com, beginning today, Monday, November 23, 2020, and will be available for 14 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What is Akouos's recent announcement regarding a virtual fireside chat?

Akouos announced that CEO Manny Simons participated in a pre-recorded fireside chat for the Piper Sandler 32nd Annual Virtual Healthcare Conference, available for on-demand viewing from November 23, 2020.

When is the Piper Sandler Virtual Healthcare Conference taking place?

The Piper Sandler 32nd Annual Virtual Healthcare Conference is scheduled for December 1-3, 2020.

How can I watch the Akouos fireside chat?

The fireside chat can be viewed on-demand on Akouos's investor relations website starting November 23, 2020, for 14 days.

What is the focus of Akouos as a company?

Akouos focuses on developing precision genetic therapies aimed at restoring and preserving hearing for individuals with disabling hearing loss.

What technology does Akouos utilize for its therapies?

Akouos leverages a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach for its gene therapies.